Skip to main content
. 2017 Dec 12;46(4):1584–1600. doi: 10.1093/nar/gkx1239

Figure 6.

Figure 6.

Design and clinical status of oligonucleotides drugs discussed in this review. Source material for this figure is cited as Supplementary Data. For Inclisiran, Fitusiran, and Givosiran, we could not locate publically available information and the structures shown below are based on the cited descriptions of this class of compound.